{"filing":{"accession_number":"0001171843-26-005913","cik":"0001581178","ticker":"EPRX","company_name":"EUPRAXIA PHARMACEUTICALS INC.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"f6k_090426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581178/000117184326005913/f6k_090426.htm"},"events":[{"id":31820,"run_id":29219,"accession_number":"0001171843-26-005913","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The press release announces that Eupraxia's common shares \"have commenced trading on the Nasdaq Global Select Market,\" representing a transfer from the Nasdaq Capital Market to Nasdaq's highest market tier. While this is technically an upgrade rather than a delisting risk, the delisting_risk category encompasses \"transfer of listing\" per the taxonomy. The move to the Global Select Market—Nasdaq's most stringent tier—is material to investors as it signals improved financial and liquidity standing and enhanced corporate governance compliance, affecting the registrant's market positioning and investor perception.","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34824,"accession_number":"0001171843-26-005913","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces that Eupraxia's common shares \"have commenced trading on the Nasdaq Global Select Market,\" representing a transfer from the Nasdaq Capital Market to Nasdaq's highest market tier. While this is technically an upgrade rather than a delisting risk, the delisting_risk category encompasses \"transfer of listing\" per the taxonomy. The move to the Global Select Market—Nasdaq's most stringent tier—is material to investors as it signals improved financial and liquidity standing and enhanced corporate governance compliance, affecting the registrant's market positioning and investor perception.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:05:43.476330+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34824,"accession_number":"0001171843-26-005913","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces that Eupraxia's common shares \"have commenced trading on the Nasdaq Global Select Market,\" representing a transfer from the Nasdaq Capital Market to Nasdaq's highest market tier. While this is technically an upgrade rather than a delisting risk, the delisting_risk category encompasses \"transfer of listing\" per the taxonomy. The move to the Global Select Market—Nasdaq's most stringent tier—is material to investors as it signals improved financial and liquidity standing and enhanced corporate governance compliance, affecting the registrant's market positioning and investor perception.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T12:05:43.476330+00:00","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-09-08"}]}